Becton Dickinson & Co. recalled 2,050 units of its EpiCenter Microbiology Data Management System on September 23, 2025. Unauthorized access to product service credentials may compromise patient data. The recall affects models distributed worldwide, including the U.S. and Puerto Rico.
Product service credentials used by some BD technical support teams to access certain BD products were accessed by an unauthorized actor. Until these product service credentials are updated, there is a risk of unauthorized access that may impact the confidentiality, integrity and/or availability of the relevant products and associated data.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Becton Dickinson & Co. or your healthcare provider for instructions. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The recall includes the following catalog numbers: 441002, 441421, 445398, and 443971. The affected systems were sold worldwide, including the U.S., Guam, and Puerto Rico. No specific price was mentioned.
Unauthorized access to service credentials creates a risk of compromised data confidentiality, integrity, and availability. This could affect sensitive patient information and overall system performance.
No specific incidents or injuries have been reported related to this recall. However, the potential for unauthorized access poses a significant risk.
Stop using the device immediately. Contact Becton Dickinson & Co. or your healthcare provider for further instructions. The company will notify affected users through various methods, including email and press release.
For assistance, call Becton Dickinson & Co. at 1-800-XXX-XXXX or visit their website at www.bd.com. Further details are available on the FDA's recall page.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.